Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tamsulosin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 10/20 | 0.96 |
| ▸ | ADRA1D known ✓ | P25100 | 9/20 | 0.96 |
| ▸ | ADRA1B known ✓ | P35368 | 9/20 | 0.96 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.96 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.96 |
| ▸ | HTR1A | P08908 | 2/20 | 0.96 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.96 |
| ▸ | DRD2 | P14416 | 2/20 | 0.96 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.96 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.96 |
| ▸ | HTR2A | P28223 | 2/20 | 0.96 |
| ▸ | DRD3 | P35462 | 2/20 | 0.96 |
| ▸ | HTR2B | P41595 | 2/20 | 0.96 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.96 |
| ▸ | HTR7 | P34969 | 1/20 | 0.96 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.96 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tamsulosin SCHEMBL9316638 | 0.98 | ADRA1A (0.96) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL30465862 | 0.98 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL29566149 | 0.98 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL29599595 | 0.98 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL29363851 | 0.98 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL53998 | 0.98 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL30361066 | 0.98 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL29588704 | 0.98 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL34378 | 0.98 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL3343160 | 0.98 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8744 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4422599-B1 | TADALAFIL ORAL SUSPENSION | FARMALIDER SA (ES) | 2026-01-28 | — | — | EP | claimed |
| US-20250241911-A1 | TADALAFIL ORAL SUSPENSION | FARMALÍDER, S.A. (ES) | 2025-07-31 | — | — | US | claimed |
| EP-4566590-A1 | TASTE-MASKING MICROSPHERE, PREPARATION PROCESS THEREFOR, AND USE THEREOF | Harbin Kanon Pharmaceutical Co., Ltd (CN) | 2025-06-11 | — | — | EP | claimed |
| CN-120084747-A | Method for measuring substitution degree of three hydroxypropylated polysaccharides by infrared spectrometry | 青岛科技大学 | 2025-06-03 | — | — | CN | claimed |
| EP-3013327-B1 | PHARMACEUTICAL CAPSULE COMPOSITE FORMULATION COMPRISING TADALAFIL AND TAMSULOSIN | HANMI PHARMACEUTICAL CO LTD (KR) | 2025-05-14 | — | — | EP | claimed |
| CN-119827443-A | Quick screening method for identifying consistency of lipstick cosmetics based on portable infrared spectrum | 中国检验检疫科学研究院粤港澳大湾区研究院 | 2025-04-15 | — | — | CN | claimed |
| CN-119405627-B | Tamsulosin sustained-release capsule based on instant coating and preparation method thereof | 安若维他药业泰州有限公司 | 2025-04-15 | — | — | CN | claimed |
| CN-119715438-A | Identification of citrus peel based on two-dimensional infrared correlation spectroscopy in combination with chemometrics | 吉林化工学院 | 2025-03-28 | — | — | CN | claimed |
| CN-119555621-A | Method for predicting cerebral hematoma injury time based on Fourier infrared spectrum technology | 重庆医科大学 | 2025-03-04 | — | — | CN | claimed |
| EP-4512392-A2 | ORALLY-ADMINISTERED PREPARATION CONTAINING SOLIFENACIN AND TAMSULOSIN | Adalvo Limited (MT) | 2025-02-26 | — | — | EP | claimed |
| US-20020142050-A1 | Porous drug matrices and methods of manufacture thereof | ACUSPHERE INC. | 2002-10-03 | — | — | US | claimed |
| WO-2002047607-A2 | PROCESS FOR THE PREPARATION OF A FAST DISSOLVING DOSAGE FORM | RANBAXY LABORATORIES LIMITED (IN) | 2002-06-20 | — | — | WO | claimed |
| EP-1203582-A1 | MEDICINAL COMPOSITIONS FOR TREATING LOWER UROPATHY | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2002-05-08 | — | — | EP | claimed |
| CN-1346268-A | Pharmaceutical composition for treating lower urinary tract disease | YAMANOUCHI PHARMA CO LTD (JP) | 2002-04-24 | — | — | CN | claimed |
| EP-1180020-A2 | POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF | Acusphere, Inc. (US) | 2002-02-20 | — | — | EP | claimed |
| WO-2000072827-A9 | POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF | ACUSPHERE INC (US) | 2002-01-31 | — | — | WO | claimed |
| US-20010028897-A1 | Compositions and treatment methods for benign prostatic hypertrophy | HAMMERLY MILTON (US) | 2001-10-11 | — | — | US | claimed |
| CN-1312711-A | Pharmaceutical composition for treating dysuria | YAMANOUCHI PHARMA CO LTD (JP) | 2001-09-12 | — | — | CN | claimed |
| EP-1088551-A1 | MEDICINAL COMPOSITIONS FOR TREATING EVACUATORY INSUFFICIENCY | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2001-04-04 | — | — | EP | claimed |
| WO-2000072827-A2 | POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF | ACUSPHERE, INC. (US) | 2000-12-07 | — | — | WO | claimed |